A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients...

Area of Science:

• Pediatric Hematology
• Transplantation Immunology
• Oncology

Background:

• Acute graft-versus-host disease (GVHD) is a major complication following allogeneic hematopoietic cell transplantation (HCT) in children.
• Current clinical grading modestly predicts treatment response and survival, necessitating improved risk stratification tools.

Purpose of the Study:

• To develop and validate a risk stratification system for pediatric patients experiencing acute GVHD at the onset of treatment.
• To predict the risk of 6-month non-relapse mortality (NRM) in this population.

Main Methods:

• Validated the MAGIC algorithm probabilities (MAPs) and Minnesota risk score in a multicenter cohort of 315 pediatric patients.
• Developed and validated a novel risk model combining Minnesota risk and biomarker scores in training and validation cohorts.

Main Results:

• MAPs created 3 risk groups with distinct outcomes and were more accurate than Minnesota risk for NRM prediction (AUC, .79 vs .62).
• The novel combined model demonstrated superior accuracy (AUC .87) in the validation cohort, stratifying patients into groups with significantly different 6-month NRM (5% vs 38%).

Conclusions:

• The MAGIC algorithm probabilities (MAPs) are validated as prognostic biomarkers in pediatric GVHD.
• A novel risk stratification combining clinical (Minnesota) and biomarker risk offers superior prediction of NRM, enabling tailored therapeutic strategies in pediatric HCT.